Physicochemical stability, pharmacokinetic, and biodistribution evaluation of paclitaxel solid dispersion prepared using supercritical antisolvent process

Drug Development and Industrial Pharmacy

Volumn 37, Issue 6, 2011, Pages 628-637

  Shanmugam, Srinivasan ^a   Park, Jae Hyun ^a   Chi, Sang Cheol ^b   Yong, Chul Soon ^c   Choi, Han Gon ^d   Woo, Jong Soo ^a  

^a Hanmi Pharmaceutical Co Ltd   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c Yeungnam University   (South Korea)

^d Hanyang University   (South Korea)

Author keywords

accelerated stress stability; organ distribution; Paclitaxel solid dispersion; pharmacokinetics; supercritical antisolvent process

Indexed keywords

PACLITAXEL;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BRAIN; BULK DENSITY; CONTROLLED STUDY; CRYSTALLIZATION; DISPERSION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG SCREENING; DRUG SOLUBILITY; DRUG STABILITY; DRUG STORAGE; DRUG SYNTHESIS; KIDNEY; LIVER; LUNG; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRECIPITATION; RAT; SOLID STATE; STRESS; SUPERCRITICAL ANTISOLVENT PROCESS; SUPERCRITICAL FLUID; TURBIDITY;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; CRYSTALLIZATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG STABILITY; DRUG STORAGE; MALE; PACLITAXEL; RATS; RATS, SPRAGUE-DAWLEY; TEMPERATURE; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 79955966031     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2010.533682     Document Type: Article

References (71)

1. Rowinsky EK, Donehower RC. (1995). Paclitaxel (Taxol). N Engl J Med 332:1004-1014.
2. Wall ME, Wani MC. (1995). Camptothecin and Taxol: discovery to clinic-thirteenth Bruce F. Cain Memorial Award Lecture. Cancer Res 55:753-760.
3. Straubinger RM, Sharma A, Sharma US, Balasubramanian SV. (1995). Taxane Anticancer Agents. Washington, DC: ACS Publications.
4. Hamoudeh M, Diab R, Fessi H, Dumontet C, Cuchet D. (2008). Paclitaxel-loaded microparticles for intratumoral administration via the TMT technique: preparation, characterization, and preliminary antitumoral evaluation. Drug Dev Ind Pharm 34:698-707. (Pubitemid 351962345)
5. Huizing MT, Misser VH, Pieters RC, ten Bokkel Huinink WW, Veenhof CH, Vermorken JB, Pinedo HM, Beijnen JH. (1995). Taxanes: a new class of antitumor agents. Cancer Invest 13:381-404.
6. Kollipara S, Bende G, Movva S, Saha R. (2010). Application of rotatable central composite design in the preparation and optimization of poly(lactic-co-glycolic acid) nanoparticles for controlled delivery of paclitaxel. Drug Dev Ind Pharm 36:1377-1387.
7. Wu L, Tang C, Yin C. (2010). Folate-mediated solid-liquid lipid nanoparticles for paclitaxel-coated poly(ethylene glycol). Drug Dev Ind Pharm 36:439-448.
8. Han J, Washington C, Davis SS. (2007). Design and evaluation of an emulsion vehicle for paclitaxel. II. Suppression of the crystallization of paclitaxel by freeze-drying technique. Drug Dev Ind Pharm 33:1151-1157. (Pubitemid 350034840)
9. Howrie DL, Ptachcinski RJ, Griffith BP, Hardesty RJ, Rosenthal JT, Burckart GJ, Venkataramanan R. (1985). Anaphylactoid reactions associated with parenteral cyclosporine use: possible role of Cremophor EL. Drug Intell Clin Pharm 19:425-427. (Pubitemid 15056453)
10. O' Dwyer PJ, King SA, Fortner CL, Leyland-Jones B. (1986). Hypersensitivity reactions to teniposide (VM-26): an analysis. J Clin Oncol 4:1262-1269. (Pubitemid 16043878)
11. Webster LK, Cosson EJ, Stokes KH, Millward MJ. (1996). Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice. Brit J Cancer 73:522-524.
12. Ellis AG, Crinis NA, Webster LK. (1996). Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80. Cancer Chemother Pharmacol 38:81-87. (Pubitemid 26097553)
13. Chervinsky DS, Brecher ML, Baker RM, Hoelcle MJ, Tebbi CK. (1993). Reversal of C1300 murine neuroblastoma multidrug resistance by Cremophor EL, a solvent for cyclosporin A. Cancer Biother 8:67-75. (Pubitemid 23295655)
14. Friche E, Jensen PB, Sehested M, Demant EJ, Nissen NN. (1990). The solvents Cremophor EL and Tween 80 modulate daunorubicin resistance in the multidrug resistant Ehrlich ascites tumor. Cancer Commun 2:297-303. (Pubitemid 20380453)
15. Kongshaug M, Cheng LS, Moan J, Rimington C. (1991). Interaction of Cremophor EL with human plasma. Int J Biochem 23:473-478.
16. Sykes E, Woodburn K, Decker D, Kessel D. (1994). Effects of Cremophor EL on distribution of Taxol to serum lipoproteins. Br J Cancer 70:401-404. (Pubitemid 24268537)
17. Webster L, Linsenmeyer M, Millward M, Morton C, Bishop J, Woodcock D. (1993). Measurement of Cremophor EL following Taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype. J Natl Cancer Inst 85:1685-1690. (Pubitemid 23315427)
18. Woodcock DM, Jefferson S, Linsenmeyer ME, Crowther PJ, Chojnowski GM, Williams B, Bertoncello I. (1990). Reversal of the multidrug resistance phenotype with Cremophor EL, a common vehicle for water-insoluble vitamins and drugs. Cancer Res 50:4199-4203. (Pubitemid 20225651)
19. Dye D, Watkins J. (1980). Suspected anaphylactic reaction to Cremophor EL. Br Med J 280:1353. (Pubitemid 10124276)
20. Lorenz W, Reimann HJ, Schmal A, Dormann P, Schwarz B, Neugebauer E, Doenicke A. (1977). Histamine release in dogs by Cremophor E1 and its derivatives: oxethylated oleic acid is the most effective constituent. Agents Actions 7:63-67. (Pubitemid 8070781)
21. Panchagnula R. (1998). Pharmaceutical aspects of paclitaxel. Int J Pharm 172:1-5.
22. Simamora P, Dannenfelser RM, Tabibi SE, Yalkowsky SH. (1998). Emulsion formulations for intravenous administration of paclitaxel. PDA J Pharm Sci Technol 52:170-172. (Pubitemid 28427711)
23. Alkan-Onyuksel H, Ramakrishnan S, Chai HB, Pezzuto JM. (1994). A mixed micellar formulation suitable for the parenteral administration of Taxol. Pharm Res 11:206-212. (Pubitemid 24076213)
24. Shieh MF, Chu IM, Lee CJ, Kan P, Hau DM, Shieh JJ. (1997). Liposomal delivery system for Taxol. J Ferment Bioeng 83:12-15.
25. Bilensoy E, Gürkaynak O, Dogan AL, Hincal AA. (2008). Safety and efficacy of amphiphilic beta-cyclodextrin nanoparticles for paclitaxel delivery. Int J Pharm 347:163-170. (Pubitemid 350180328)
26. Dordunoo SK, Jackson JK, Arsenault LA, Oktaba AM, Hunter WL, Burt HM. (1995). Taxol encapsulation in poly(epsilon-caprolactone) microspheres. Cancer Chemother Pharmacol 36:279-282.
27. Tarr BD, Sambandan TG, Yalkowsky SH. (1987). A new parenteral emulsion for the administration of Taxol. Pharm Res 4:162-165. (Pubitemid 17089608)
28. Kang Y, Yin G, Ouyang P, Huang Z, Yao Y, Liao X, Chen A, Pu X. (2008). Preparation of PLLA/PLGA microparticles using solution enhanced dispersion by supercritical fluids (SEDS). J Colloid Interface Sci 322:87-94.
29. Lee MK, Lim SJ, Kim CK. (2007). Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles. Biomaterials 28:2137-2146.
30. Lee LY, Wang CH, Smith KA. (2008). Supercritical antisolvent production of biodegradable micro- and nanoparticles for controlled delivery of paclitaxel. J Control Release 125:96-106. (Pubitemid 350299604)
31. Silva TD, Arantes VT, Resende JA, Speziali NL, de Oliveira RB, Vianna-Soares CD. (2010). Preparation and characterization of solid dispersion of simvastatin. Drug Dev Ind Pharm 36:1348-1355.
32. Khattab IS, Nada A, Zaghloul AA. (2010). Physicochemical characterization of gliclazide-macrogol solid dispersion and tablets based on optimized dispersion. Drug Dev Ind Pharm 36:893-902.
33. Seetapan N, Bejrapha P, Srinuanchai W, Puttipipatkhachorn S, Ruktanonchai U. (2010). Nondestructive rheological measurement of aqueous dispersions of solid lipid nanoparticles: effects of lipid types and concentrations on dispersion consistency. Drug Dev Ind Pharm 36:1005-1015.
34. Maghsoodi M, Sadeghpoor F. (2010). Preparation and evaluation of solid dispersions of Piroxicam and Eudragit S100 by spherical crystallization technique. Drug Dev Ind Pharm 36:917-925.
35. Taylor LS, Zografi G. (1997). Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersions. Pharm Res 14:1691-1698. (Pubitemid 28062912)
36. Matsumoto T, Zografi G. (1999). Physical properties of solid molecular dispersions of indomethacin with poly(vinylpyrrolidone) and poly(vinylpyrrolidone-co-vinylacetate) in relation to indomethacin crystallization. Pharm Res 16:1722-1728. (Pubitemid 29530405)
37. Pignatello R, Ferro M, De Guidi G, Salemi G, Vandelli MA, Guccione S, Geppi M, Forte C, Puglisi G. (2001). Preparation, characterisation and photosensitivity studies of solid dispersions of diflunisal and Eudragit RS100 and RL100. Int J Pharm 218:27-42. (Pubitemid 32406154)
38. Aceves JM, Cruz R, Hernandez E. (2000). Preparation and characterization of Furosemide-Eudragit controlled release systems. Int J Pharm 195:45-53. (Pubitemid 30089489)
39. Oth MP, Moes AJ. (1989). Sustained release solid dispersions of indomethacin with Eudragit RS and RL. Int J Pharm 55:157-174.
40. Kompella UB, Koushik K. (2001). Preparation of drug delivery systems using supercritical fluid technology. Crit Rev Ther Drug Carrier Syst 18:173-199. (Pubitemid 32378147)
41. Jung J, Perrut M. (2001). Particle design using supercritical fluids: literature and patent survey. J Supercrit Fluids 20:179-219. (Pubitemid 32607129)
42. Park JH, Chi SC, Woo JS. (2008). Preparation and evaluation of paclitaxel solid dispersion by supercritical antisolvent process. J Kor Pharm Sci 38:241-247.
43. Park JH, Chi SC, Lee WS, Lee WM, Koo YB, Yong CS, Choi HG, Woo JS. (2009). Toxicity studies of Cremophor-free paclitaxel solid dispersion formulated by a supercritical antisolvent process. Arch Pharm Res 32:139-148.
44. U.S. Pharmacopeia. USP 29-NF 24. General Chapters: Osmolality and Osmolarity. Measurement of Osmolarity, p. 2718.
45. Nornoo AO, Osborne DW, Chow DS. (2008). Cremophor-free intravenous microemulsions for paclitaxel I: formulation, cytotoxicity and hemolysis. Int J Pharm 349:108-116. (Pubitemid 350299695)
46. Karavas E, Georgarakis E, Bikiaris D, Thomas T, Katsos V, Xenakis A. (2001). Hydrophilic matrices as carriers in felodipine solid dispersion systems. Progr Colloid Polym Sci 118:149-152.
47. Weuts I, Kempen D, Verreck G, Decorte A, Heymans K, Peeters J, Brewster M, Van den Mooter G. (2005). Study of the physicochemical properties and stability of solid dispersions of loperamide and PEG6000 prepared by spray drying. Eur J Pharm Biopharm 59:119-126. (Pubitemid 39573443)
48. Leuner C, Dressman J. (2000). Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm 50:47-60. (Pubitemid 30326688)
49. Won DH, Kim MS, Lee S, Park JS, Hwang SJ. (2005). Improved physicochemical characteristics of felodipine solid dispersion particles by supercritical anti-solvent precipitation process. Int J Pharm 301:199-208. (Pubitemid 41206604)
50. Hirasawa N, Ishise S, Miyata H, Danjo K. (2004). Application of nilvadipine solid dispersion to tablet formulation and manufacturing using crospovidone and methylcellulose as dispersion carriers. Chem Pharm Bull 52:244-247. (Pubitemid 41656758)
51. Shamblin SL, Zografi G. (1998). Enthalpy relaxation in binary amorphous mixtures containing sucrose. Pharm Res 15:1828-1834. (Pubitemid 29034830)
52. Yoshioka M, Hancock BC, Zografi G. (1995). Inhibition of indomethacin crystallization in poly(vinylpyrrolidone) coprecipitates. J Pharm Sci 84:983-986.
53. Mura P, Faucci MT, Manderioli A, Bramanti G, Parrini P. (1999). Thermal behavior and dissolution properties of naproxen from binary and ternary solid dispersions. Drug Dev Ind Pharm 25:257-264. (Pubitemid 29108671)
54. Karavas E, Georgarakis E, Sigalas MP, Avgoustakis K, Bikiaris D. (2007). Investigation of the release mechanism of a sparingly water-soluble drug from solid dispersions in hydrophilic carriers based on physical state of drug, particle size distribution and drug-polymer interactions. Eur J Pharm Biopharm 66:334-347. (Pubitemid 46778978)
55. Karavas E, Georgarakis E, Bikiaris D. (2006). Felodipine nanodispersions as active core for predictable pulsatile chronotherapeutics using PVP/HPMC blends as coating layer. Int J Pharm 313:189-197.
56. Stability Testing for New Dosage Forms, Q1C second revision. ICH Guidelines, 1996.
57. Alhneck C, Zografi G. (1990). The molecular basis of moisture effects on the physical and chemical stability of drugs in the solid state. Int J Pharm 62:87-95. (Pubitemid 20261777)
58. Fitzpatrick S, McCabe JF, Petts CR, Booth SW. (2002). Effect of moisture on polyvinylpyrrolidone in accelerated stability testing. Int J Pharm 246:143-151. (Pubitemid 35247987)
59. Ghebremeskel AN, Vemavarapu C, Lodaya M. (2006). Use of surfactants as plasticizers in preparing solid dispersions of poorly soluble API: stability testing of selected solid dispersions. Pharm Res 23:1928-1936. (Pubitemid 44200557)
60. Papageorgiou GZ, Papadimitriou S, Karavas E, Georgarakis E, Docoslis A, Bikiaris D. (2009). Improvement in chemical and physical stability of fluvastatin drug through hydrogen bonding interactions with different polymer matrices. Curr Drug Deliv 6:101-112.
61. Brown T, Havlin K, Weiss G, Cagnola J, Koeller J, Kuhn J, Rizzo J, Craig J, Phillips J, Von Hoff D. (1991). A phase I trial of Taxol given by a 6-hour intravenous infusion. J Clin Oncol 9:1261-1267.
62. Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH. (1996). Tissue distribution, metabolism and excretion of paclitaxel in mice. Anticancer Drugs 7:78-86. (Pubitemid 26059949)
63. Rowinsky EK, Donehower RC. (1993). The clinical pharmacology of paclitaxel (Taxol). Semin Oncol 20:16-25.
64. van Tellingen O, Huizing MT, Panday VR, Schellens JH, Nooijen WJ, Beijnen JH. (1999). Cremophor EL causes (pseudo-) nonlinear pharmacokinetics of paclitaxel in patients. Br J Cancer 81:330-335. (Pubitemid 29423714)
65. Sonnichsen DS, Hurwitz CA, Pratt CB, Shuster JJ, Relling MV. (1994). Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. J Clin Oncol 12:532-538. (Pubitemid 24079895)
66. Walle T, Walle UK, Kumar GN, Bhalla KN. (1995). Taxol metabolism and disposition in cancer patients. Drug Metab Dispos 23:506-512.
67. Gianni L, Kearns CM, Giani A, Capri G, ViganóL, Lacatelli A, Bonadonna G, Egorin MJ. (1995). Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/ pharmacodynamic relationships in humans. J Clin Oncol 13:180-190.
68. Gallo JM, Li S, Guo P, Reed K, Ma J. (2003). The effect of P-glycoprotein on paclitaxel brain and brain tumor distribution in mice. Cancer Res 63:5114-5117. (Pubitemid 37022652)
69. Stewart DJ. (1994). A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors. J Neurooncol 20:121-139. (Pubitemid 24309908)
70. Heimans JJ, Vermorken JB, Wolbers JG, Eeltink CM, Meijer OW, Taphoorn MJ, Beijnen JH. (1994). Paclitaxel (Taxol) concentrations in brain tumor tissue. Ann Oncol 5:951-953.
71. Glantz MJ, Choy H, Kearns CM, Mills PC, Wahlberg LU, Zuhowski EG, Calabresi P, Egorin MJ. (1995). Paclitaxel disposition in plasma and central nervous systems of humans and rats with brain tumors. J Natl Cancer Inst 87:1077-1081.